Natus Medical Inc  

(Public, NASDAQ:BABY)   Watch this stock  
Find more results for BABY
-0.50 (-1.20%)
Oct 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 40.90 - 41.65
52 week 29.54 - 51.05
Open 41.30
Vol / Avg. 455,072.00/459,727.00
Mkt cap 1.36B
P/E 33.33
Div/yield     -
EPS 1.23
Shares 32.94M
Beta 0.78
Inst. own 89%
Oct 19, 2016
Q3 2016 Natus Medical Inc Earnings Call
Oct 19, 2016
Q3 2016 Natus Medical Inc Earnings Release
Sep 26, 2016
Natus Medical Inc to Acquire GN Otometrics Business from GN Store Nord A/S - M&A Call
Sep 15, 2016
Natus Medical Inc at Credit Suisse Small & Mid Cap Conference
Sep 12, 2016
Natus Medical Inc at Morgan Stanley Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 10.95% 10.09%
Operating margin 14.52% 14.23%
EBITD margin - 19.05%
Return on average assets 8.79% 8.30%
Return on average equity 10.69% 10.20%
Employees 1,067 -
CDP Score - -


6701 Koll Center Pkwy Ste 120
PLEASANTON, CA 94566-8061
United States - Map
+1-925-2236700 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company's segment is neurology and newborn care product families. Its product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn's environment, and software systems for managing and tracking disorders and diseases for public health laboratories. It is organized into two strategic business units: Neurology and Newborn Care.

Officers and directors

Robert A. Gunst Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James B. Hawkins President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jonathan A. Kennedy Chief Financial Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
Austin F. Noll III Vice President and General Manager - Neurology Strategic Business Unit
Age: 48
Bio & Compensation  - Reuters
Kenneth M. Traverso Vice President, General Manager - Newborn Care Strategic Business Unit
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ajay A. Bhave Vice President - Global Engineering
Age: 58
Bio & Compensation  - Reuters
D. Christopher Chung M.D. Vice President - Medical Affairs, Quality & Regulatory
Age: 51
Bio & Compensation  - Reuters
Barbara R. Paul M.D. Director
Age: 60
Bio & Compensation  - Reuters
Doris E. Engibous Independent Director
Age: 60
Bio & Compensation  - Reuters
Kenneth E. Ludlum Independent Director
Age: 61
Bio & Compensation  - Reuters